FACULTY
Emily S. Ruiz, MD, MPH
Assistant Professor of Dermatology, Harvard Medical School
Director, High-Risk Skin Cancer Clinic, Dana-Farber Cancer Institute
Program Director, Micrographic Surgery and Dermatologic Oncology Fellowship, Brigham and Women’s Hospital
Boston, Massachusetts
PROGRAM OVERVIEW
With multiple immunotherapy treatment options and combinations available for the management of melanoma, clinicians require up-to-date guidance on the application of clinical data—including recent findings presented at ASCO—to support shared decision-making and multidisciplinary care. In this concise program, Dr. Emily Ruiz reviews current evidence-based guidelines, presents clinical data informing treatment decisions, and demonstrates best practices for applying this data to patients with melanoma.
TARGET AUDIENCE
This activity is designed to meet the educational needs of clinicians who are involved in the management of patients with NMSCs. This may include dermato-oncologists, oncologists, and surgeons with varying skin cancer-specific expertise, and associated advanced practice providers (APPs; e.g., oncology nurses, nurse practitioners, and physician assistants), and other clinicians involved in the treatment and care of patients with NMSC.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess tumor type, patient characteristics, disease profile, risk factors, and prognosis to select the most appropriate therapeutic strategy for individuals with NMSC.
- Apply the available and emerging data for immune checkpoint inhibitors (ICIs) in the neoadjuvant and adjuvant settings to guide treatment decisions for patients with NMSCs.
- Use an MDT structure and an SDM approach to provide effective care for patients with NMSC.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Emily S. Ruiz, MD, MPH | Consulting Fees: Regeneron, Checkpoint Therapeutics |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Melissa Johnson, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, (CME Contact) for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Millena Papastavrou, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Kim L. Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use their clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (e.g., dietary, physical, etc.). Please contact Med Learning Group prior to the live event at [email protected]
RELEASED DATE: July 31, 2025
EXPIRATION DATE: July 31, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
